1,25-Dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 124, Issue 1-2, 2011, Pages 1-9

  Clinckspoor, Isabelle ^a   Verlinden, Lieve ^a   Overbergh, Lutgart ^a   Korch, Christopher ^b   Bouillon, Roger ^a   Mathieu, Chantal ^a   Verstuyf, Annemieke ^a   Decallonne, Brigitte ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cancer; Nonsteroidal analog; Paclitaxel; SAHA; Thyroid; Vitamin D

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CD 578; MESSENGER RNA; PACLITAXEL; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VORINOSTAT;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CLONOGENIC ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; THYROID CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; HYDROXAMIC ACIDS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; THYROID NEOPLASMS;

EID: 79952038946     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.12.008     Document Type: Article

References (41)

1. S. (Pubitemid 36173719)
2. C. Are, and A.R. Shaha Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Ann. Surg. Oncol. 13 2006 453 464
3. J.W. Park, and O.H. Clark Redifferentiation therapy for thyroid cancer Surg. Clin. N. Am. 84 2004 921 943 (Pubitemid 38622425)
4. R. Bouillon, G. Eelen, L. Verlinden, C. Mathieu, G. Carmeliet, and A. Verstuyf Vitamin D and cancer J. Steroid Biochem. Mol. Biol. 102 2006 156 162 (Pubitemid 44781185)
5. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nat. Rev. Cancer 7 2007 684 700 (Pubitemid 47327412)
6. W. Liu, S.L. Asa, I.G. Fantus, P.G. Walfish, and S. Ezzat Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways Am. J. Pathol. 160 2002 511 519 (Pubitemid 34160328)
7. 3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer Endocrinology 145 2004 5840 5846 (Pubitemid 39564625)
8. 3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness Mol. Endocrinol. 19 2005 2349 2357 (Pubitemid 41252827)
9. K. Kostner, N. Denzer, C.S. Muller, R. Klein, W. Tilgen, and J. Reichrath The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature Anticancer Res. 29 2009 3511 3536
10. M. Penna-Martinez, E. Ramos-Lopez, J. Stern, N. Hinsch, M.L. Hansmann, I. Selkinski, F. Grunwald, C. Vorlander, R.A. Wahl, W.O. Bechstein, S. Zeuzem, K. Holzer, and K. Badenhoop Vitamin D receptor polymorphisms in differentiated thyroid carcinoma Thyroid 19 2009 623 628
11. 3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma J. Histochem. Cytochem. 54 2006 355 361 (Pubitemid 43291280)
12. R. Bouillon, L. Verlinden, G. Eelen, C.P. De, M. Vandewalle, C. Mathieu, and A. Verstuyf Mechanisms for the selective action of vitamin D analogs J. Steroid Biochem. Mol. Biol. 97 2005 21 30 (Pubitemid 41546210)
13. Y. Wu, C.P. De, M. Vandewalle, R. Bouillon, and A. Verstuyf Vitamin D(3): synthesis of seco-C-9,11-bisnor-17-methyl-1 alpha,25-dihydroxyvitamin D(3) analogues Bioorg. Med. Chem. Lett. 12 2002 1633 1636 (Pubitemid 34569260)
14. 3 analogs stabilize helix 12 of the vitamin D receptor Chem. Biol. 15 2008 1029 1034
15. T. Higashiyama, Y. Ito, M. Hirokawa, M. Fukushima, T. Uruno, A. Miya, F. Matsuzuka, and A. Miyauchi Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma Thyroid 20 2010 7 14
16. K.B. Ain, M.J. Egorin, and P.A. DeSimone Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group Thyroid 10 2000 587 594 (Pubitemid 30670619)
17. C.S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V.M. Richon, P.A. Marks, and N. Mitsiades Novel histone deacetylase inhibitors in the treatment of thyroid cancer Clin. Cancer Res. 11 2005 3958 3965 (Pubitemid 40685618)
18. Q.T. Luong, J. O'Kelly, G.D. Braunstein, J.M. Hershman, and H.P. Koeffler Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo Clin. Cancer Res. 12 2006 5570 5577 (Pubitemid 44497275)
19. W.C. van Staveren, D.W. Solis, L. Delys, L. Duprez, G. Andry, B. Franc, G. Thomas, F. Libert, J.E. Dumont, V. Detours, and C. Maenhaut Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype Cancer Res. 67 2007 8113 8120 (Pubitemid 47395146)
20. W.C. van Staveren, D.Y. Solis, A. Hebrant, V. Detours, J.E. Dumont, and C. Maenhaut Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta 1795 2009 92 103
21. J.J. Lee, T. Foukakis, J. Hashemi, L. Grimelius, N.E. Heldin, G. Wallin, C. Rudduck, W.O. Lui, A. Hoog, and C. Larsson Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models Thyroid 17 2007 289 301 (Pubitemid 46776132)
22. R.E. Schweppe, J.P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J.A. Knauf, J.A. Fagin, L.A. Marlow, J.A. Copland, R.C. Smallridge, and B.R. Haugen Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification J. Clin. Endocrinol. Metab. 93 2008 4331 4341 (Pubitemid 352789529)
23. L. Overbergh, A. Giulietti, D. Valckx, R. Decallonne, R. Bouillon, and C. Mathieu The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression J. Biomol. Tech. 14 2003 33 43
24. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
25. 3 on the expression of DNA replication genes J. Bone Miner. Res. 19 2004 133 146 (Pubitemid 41295146)
26. 3 and its analogue 22-oxacalcitriol against human anaplastic thyroid carcinoma cell lines in vitro Int. J. Mol. Med. 4 1999 611 614
27. H.C. Freake, and I. MacIntyre Specific binding of 1,25- dihydroxycholecalciferol in human medullary thyroid carcinoma Biochem. J. 206 1982 181 184 (Pubitemid 12052616)
28. 3 on thyrotropin-induced iodide uptake Mol. Cell. Endocrinol. 81 1991 25 31
29. P. Siironen, S. Nordling, J. Louhimo, R. Haapiainen, and C. Haglund Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer Tumour Biol. 26 2005 50 56 (Pubitemid 40529298)
30. B. Saltman, B. Singh, C.V. Hedvat, V.B. Wreesmann, and R. Ghossein Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression Surgery 140 2006 899 905
31. 3 J. Biol. Chem. 280 2005 37319 37330 (Pubitemid 41642337)
32. T. Higashiyama, Y. Ito, M. Hirokawa, M. Fukushima, T. Uruno, A. Miya, F. Matsuzuka, and A. Miyauchi Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma Thyroid 2009
33. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo Breast Cancer Res. Tr. 53 1999 113 120 (Pubitemid 29161117)
34. P.A. Hershberger, W.D. Yu, R.A. Modzelewski, R.M. Rueger, C.S. Johnson, D.L. Trump, and Calcitriol (1,25-Dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis Clin. Cancer Res. 7 2001 1043 1051 (Pubitemid 32708744)
35. J.R. Muindi, Y. Peng, D.M. Potter, P.A. Hershberger, J.S. Tauch, M.J. Capozzoli, M.J. Egorin, C.S. Johnson, and D.L. Trump Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel Clin. Pharmacol. Ther. 72 2002 648 659 (Pubitemid 36021004)
36. T. Akagi, Q.T. Luong, D. Gui, J. Said, J. Selektar, A. Yung, C.M. Bunce, G.D. Braunstein, and H.P. Koeffler Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells Br. J. Cancer 99 2008 781 788
37. W.K. Kelly, O.A. O'Connor, L.M. Krug, J.H. Chiao, M. Heaney, T. Curley, B. MacGregore-Cortelli, W. Tong, J.P. Secrist, L. Schwartz, S. Richardson, E. Chu, S. Olgac, P.A. Marks, H. Scher, and V.M. Richon Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J. Clin. Oncol. 23 2005 3923 3931 (Pubitemid 46218695)
38. J.A. Woyach, R.T. Kloos, M.D. Ringel, D. Arbogast, M. Collamore, J.A. Zwiebel, M. Grever, M. Villalona-Calero, and M.H. Shah Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma J. Clin. Endocrinol. Metab. 94 2009 164 170
39. 3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation Recent Results Cancer Res. 164 2003 83 98
40. S. Karmakar, N.L. Banik, and S.K. Ray Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice Cancer 112 2008 596 607 (Pubitemid 351186200)
41. P. Hou, E. Bojdani, and M. Xing Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways J. Clin. Endocrinol. Metab. 2009